创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

郑易林, 邵黎明. 展望2019:寻求中国生物医药企业生存与发展的新平衡点[J]. 药学进展, 2019, 43(3): 191-193.
引用本文: 郑易林, 邵黎明. 展望2019:寻求中国生物医药企业生存与发展的新平衡点[J]. 药学进展, 2019, 43(3): 191-193.
ZHENG Yilin, SHAO Liming. 2019 Outlook: Find a New Balance between Survival and Development of China's Biopharmaceutical Industry[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 191-193.
Citation: ZHENG Yilin, SHAO Liming. 2019 Outlook: Find a New Balance between Survival and Development of China's Biopharmaceutical Industry[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 191-193.

展望2019:寻求中国生物医药企业生存与发展的新平衡点

2019 Outlook: Find a New Balance between Survival and Development of China's Biopharmaceutical Industry

  • 摘要: 2018年是中国生物医药趋于理性发展的一年。2019年,在政策、经济环境的变化之下,制药企业将进入新的调整期。上海市药物研发协同创新中心召开智库圆桌会议,通过多轮头脑风暴,对我国生物医药行业进行了年度展望,提出生物医药企业需在生存与发展之间找到合适的新平衡点。

     

    Abstract: 2018 witnessed the rational development of China's biopharmaceutical industry. In 2019, with the changes in political and economic environment, biopharmaceutical enterprises will enter a new period of adjustment. At the beginning of 2019, Shanghai Center for Innovation Drug Discovery and Development (SCIDDD) held a series of roundtable brainstorming, and proposed the 2019 outlook of China's biopharmaceutical industry, emphasizing that biopharmaceutical enterprises need to find a new balance between survival and development.

     

/

返回文章
返回